Klaria submits Marketing Authorization Application for Sumatriptan Alginate Film in Europe
UPPSALA — November 29, 2022 — Klaria Pharma AB (publ) (Nasdaq Stockholm: KLAR) today announces that the Company has submitted a Marketing Authorization Application (MAA) for Sumatriptan Alginate Film for the treatment of Migraine in the European Union. Pending positive validation, Sumatriptan Alginate Film will be subject to a regulatory assessment according to the standard timeline, which would result in approval in Q1, 2024.“Sumatriptan Alginate Film addresses an important medical need in patients with migraine. With the submission of the MAA, we have now successfully done everything we